# Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia

> **NCT04659525** · PHASE4 · UNKNOWN · sponsor: **Policlinico Casilino ASL RMB** · enrollment: 50 (estimated)

## Conditions studied

- Hypercholesterolemia
- CKD Stage 5
- Chronic Kidney Disease Requiring Chronic Dialysis

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Ezetimibe
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04659525
- **Lead sponsor:** Policlinico Casilino ASL RMB
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659525, "Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04659525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*